Studies and nationwide registry studies have been performed since the J- RHYTHM study, and recently, Japanese evidence associated with pharmacological treatment of arrhythmias has become available. ACS, acute coronary syndrome ADME, absorption, distribution, met abolism, excretion AHRE, atrial high rate episode AIVR, accelerated idioventricular rhythm APD, action potential duration APTT, act ivated partial thromboplastin time ARB, angiotensin II receptor blocker ATP, adenosine triphosphate AVRT, atrioventricular reciprocating tachycardia BMI, body mass index BNP, B- type natriuretic peptide CABG, coronary arter y bypass grafting CCr, creatinine clearance CKD, chronic kidney disease COPD, chronic obstructive pulmonary disease CPR, cardiopulmonary resuscitation CPVT, c atecholaminergic polymorphic ventricular tachycardia DAD, delayed afterdepolarization DAPT, dual antiplatelet therapy dTT, dilute thrombin time DOAC, direct oral anticoagulant EAD, early afterdepolarization ES, electrical storm ECA, ecarin chromogenic assay ESUS, embolic stroke of undetermined source HBR, high bleeding risk HFpEF, heart failure with preserved ejection fract ionHFrEF, heart failure with reduced ejection fraction ICD, implantable cardioverter- defibrillator INR, international normalized ratio LQTS, long QT syndrome LVEF, left ventricular ejection frac tion OAC, oral anticoagulant OSA, obstructive sleep apnea PCI, percutaneous coronary intervention PEA, pulseless electrical activit y PJRT, permanent junctional reciprocating tachycardia PT, prothrombin time pVT, pulseless ventricular tachycardia RAS, renin– angiotensin system ROSC, return of spontaneous circulation rt- PA, recombinant tissue- type plasminogen activator SQTS, short QT syndrome SR, sarcoplasmic reticulum TdP, torsade de pointes TIA, t ransient ischemic attack T TR, time in therapeutic range Vd, volume of distribution VT, ventricular tachycardia WPW, Wolff- Parkinson- White
0 kommentar(er)
